About this episode
Pharmaceutical giants are shelling out billions of dollars lately to buy promising new drugs. Is this a sign of good financial health, or a problem with pipelines? We’ll discuss.
Plus, there’s more and more data coming out on Shein as it prepares for a U.S. IPO. We’ll break down it’s revenue numbers, and where it ranks compared to American retailers.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Power Lunch publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Power Lunch
Fed holds rates steady 4/29/26
Power Lunch
Stocks sell off as OpenAI report hits market 4/28/26
Power Lunch
Market waits for Big Tech earnings this week 4/27/26
Power Lunch
Semiconductor stocks keep surging 4/24/26
Power Lunch